

Carafate suspension (sucralfate suspension) Prior Authorization Request Form



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

MEMBER INFORMATION			
LAST NAME:	FIRST NAME:		
PHONE NUMBER:	DATE OF BIRTH:		
STREET ADDRESS:			
CITY:	STATE: ZIP CODE:		
PATIENT INSURANCE ID NUMBER:			

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: <u>https://magellanrx.com/member/external/commercial/common/doc/en-us/phi_disclosure_authorization.pdf</u>

MALE FEMALE HEIGHT (IN/CM): _____ WEIGHT (LB/KG): _____ ALLERGIES: _____

PRESCRIBER INFORMATION				
LAST NAME:	FIRST NAME:			
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:			
NPI NUMBER:	DEA NUMBER:			
PHONE NUMBER:	FAX NUMBER:			
STREET ADDRESS:				
CITY:	STATE: ZIP CODE:			
REQUESTOR (if different than prescriber):	OFFICE CONTACT PERSON:			

MEDICATION OR MEDICAL DISPENSING INFORMATION					
MEDICATION NAME:					
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:		
NEW THERAPY DURATION OF THERAPY (SPE	RENEWAL CIFIC DATES):	IF RENEWAL: DATE THERAPY INITIATED:			

Continued on next page







Carafate (sucralfate tablets/suspension) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640



MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:			
1. HAS THE PATIENT TRIED ANY OTHER MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	MEDICATIONS FOR THIS CONDITION? DURATION OF THERAPY (SPECIFY DATES):	YES (if yes, complete below) NO RESPONSE/REASON FOR FAILURE/ALLERGY:		
2. LIST DIAGNOSES:		ICD-10:		
Duodenal Ulcer ICD-10 Code(s): ICD-10 Code(s):				
3. REQUIRED CLINICAL INFORMATION: PRIOR AUTHORIZATION.	PLEASE PROVIDE ALL RELEVANT CLINIC	AL INFORMATION TO SUPPORT A		
Clinical Information: <u>Initial Request:</u> Does patient have a diagnosis other th	an a Duodenal Ulcer? 🗆 Yes 🗆 No			
 ALL PRESCRIBERS: Please acknowledge you have read and understand the following statements by checking the respective boxes: Sucralfate is FDA-approved only for the treatment of duodenal ulcers. Acknowledge: □ Sucralfate is FDA-approved only for short-term (8 weeks) use. Acknowledge: □ Sucralfate TABLETS do not require prior authorization AND cost significantly LESS (are more cost-effective) than sucralfate SUSPENSION. Acknowledge: □ Just prior to administration, a sucralfate tablet may be dissolved over 15-20 minutes in 10 mL water to prepare a liquid slurry for consumption. Acknowledge: □ 				
Has patient tried sucralfate tablets? Yes No Does patient have an absolute contraindication to the sucralfate tablets? Yes No Please submit documentation.				
Renewal Request: Is sucralfate suspension continuing to have a clinical benefit? Yes No Please submit documentation. Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?				
Please note: Not all drugs/diagnosis are information is received.	e covered on all plans. This request may	be denied unless all required		







Carafate (sucralfate tablets/suspension) Prior Authorization Request Form Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640



MEMBER'S LAST NAME: ____

______ MEMBER'S FIRST NAME: ______

ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature or Electronic I.D. Verification: _____ Date: _____ Date: _____

CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

FAX THIS FORM TO: 800-424-7640 MAIL REQUESTS TO: Magellan Rx Management Prior Authorization Program

Attn: CP - 4201 P.O. Box 64811 St. Paul, MN 55164-0811



